Genesco Earnings Calls
| Release date | May 29, 2026 |
| EPS estimate | -$2.58 |
| EPS actual | -$2.18 |
| EPS Surprise | 15.50% |
| Revenue estimate | 474.325M |
| Revenue actual | 487.025M |
| Revenue Surprise | 2.68% |
| Release date | Mar 06, 2026 |
| EPS estimate | $3.73 |
| EPS actual | $3.74 |
| EPS Surprise | 0.268% |
| Revenue estimate | 791.102M |
| Revenue actual | 799.941M |
| Revenue Surprise | 1.12% |
| Release date | Dec 04, 2025 |
| EPS estimate | $0.87 |
| EPS actual | $0.790 |
| EPS Surprise | -9.20% |
| Revenue estimate | 790.526M |
| Revenue actual | 616.217M |
| Revenue Surprise | -22.05% |
| Release date | Aug 28, 2025 |
| EPS estimate | -$1.25 |
| EPS actual | -$1.14 |
| EPS Surprise | 8.80% |
| Revenue estimate | 618.623M |
| Revenue actual | 545.965M |
| Revenue Surprise | -11.75% |
Last 4 Quarters for Genesco
Below you can see how GCO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 28, 2025 |
| Price on release | $31.04 |
| EPS estimate | -$1.25 |
| EPS actual | -$1.14 |
| EPS surprise | 8.80% |
| Date | Price |
|---|---|
| Aug 22, 2025 | $28.56 |
| Aug 25, 2025 | $28.46 |
| Aug 26, 2025 | $32.16 |
| Aug 27, 2025 | $32.99 |
| Aug 28, 2025 | $31.04 |
| Aug 29, 2025 | $31.98 |
| Sep 02, 2025 | $32.11 |
| Sep 03, 2025 | $31.59 |
| Sep 04, 2025 | $33.68 |
| 4 days before | 8.68% |
| 4 days after | 8.51% |
| On release day | 3.03% |
| Change in period | 17.93% |
| Release date | Dec 04, 2025 |
| Price on release | $24.38 |
| EPS estimate | $0.87 |
| EPS actual | $0.790 |
| EPS surprise | -9.20% |
| Date | Price |
|---|---|
| Nov 28, 2025 | $35.85 |
| Dec 01, 2025 | $35.74 |
| Dec 02, 2025 | $35.40 |
| Dec 03, 2025 | $35.25 |
| Dec 04, 2025 | $24.38 |
| Dec 05, 2025 | $22.73 |
| Dec 08, 2025 | $23.56 |
| Dec 09, 2025 | $23.47 |
| Dec 10, 2025 | $23.83 |
| 4 days before | -31.99% |
| 4 days after | -2.26% |
| On release day | -6.77% |
| Change in period | -33.53% |
| Release date | Mar 06, 2026 |
| Price on release | $26.50 |
| EPS estimate | $3.73 |
| EPS actual | $3.74 |
| EPS surprise | 0.268% |
| Date | Price |
|---|---|
| Mar 02, 2026 | $26.18 |
| Mar 03, 2026 | $26.00 |
| Mar 04, 2026 | $26.38 |
| Mar 05, 2026 | $26.09 |
| Mar 06, 2026 | $26.50 |
| Mar 09, 2026 | $25.89 |
| Mar 10, 2026 | $26.74 |
| Mar 11, 2026 | $25.77 |
| Mar 12, 2026 | $25.08 |
| 4 days before | 1.22% |
| 4 days after | -5.36% |
| On release day | -2.30% |
| Change in period | -4.20% |
| Release date | May 29, 2026 |
| Price on release | $38.37 |
| EPS estimate | -$2.58 |
| EPS actual | -$2.18 |
| EPS surprise | 15.50% |
| Date | Price |
|---|---|
| May 22, 2026 | $37.02 |
| May 26, 2026 | $37.38 |
| May 27, 2026 | $37.18 |
| May 28, 2026 | $36.38 |
| May 29, 2026 | $38.37 |
| Jun 01, 2026 | $37.26 |
| Jun 02, 2026 | $39.42 |
| Jun 03, 2026 | $38.91 |
| 4 days before | 3.65% |
| 4 days after | 1.41% |
| On release day | -2.89% |
| Change in period | 5.11% |
Genesco Earnings Call Transcript Summary of Q2 2026
Genesco reported a better-than-expected Q2 with its fourth consecutive quarter of positive comparable sales (total revenue $546M, +4%). Journeys is the clear growth driver—high-single to double-digit comps, trailing-12-month comps +~10%, strong back-to-school momentum, elevated ASPs, and Journeys 4.0 remodels (55 open; >25% sales lift) that are attracting new customers. Schuh faced a weak U.K. retail backdrop with promotional pressure and margin compression but showed signs of improvement in July/August; volatility is expected to continue. Johnston & Murphy (J&M) inflected to positive comps driven by fresher product and improved margins. Genesco Brands saw margin hits from license exits, product liquidations and tariffs, but the company highlighted a new Wrangler footwear partnership launching fall 2026. Management reiterated full-year adjusted EPS guidance of $1.30–$1.70 while raising revenue and comp assumptions (revenue growth 3–4%; comps 4–5%) but now expects greater gross margin pressure (down ~50–60 bps) and stronger SG&A operating leverage (80–100 bps FY). Balance sheet/cash: Q2 free cash flow $72M (boosted by a federal tax refund), inventory +11% to support B2S, capex guidance $55–65M, ~10.6M average shares, $29.8M remaining on buyback authorization. Key investor takeaways: Journeys’ transformation is driving share gains and higher ASPs; tariff and U.K. promotional pressure are near-term margin headwinds; company maintains FY earnings guidance while investing in Journeys growth and store remodels.
Sign In
Buy GCO